Ulcerative Colitis Medications: Risk Links and Treatment Options to Review
One common mistake with ulcerative colitis is assuming a flare is only about food or stress, when a recent medication change may also deserve review.
Several prescription and non-prescription drugs have been studied for possible links to ulcerative colitis, especially in people who may already be prone to inflammatory bowel disease. At the same time, newer ulcerative colitis medications such as biologics, IL-23 inhibitors, JAK inhibitors, and S1P receptor modulators can offer different treatment paths depending on disease severity, prior treatment history, and safety considerations.
This guide focuses on two decisions patients often face: which medication exposures may be worth reviewing if symptoms changed, and what factors matter when comparing current UC treatments.
Medication categories that often come up in UC research
An association does not prove that a drug caused ulcerative colitis, and many people use these medicines without developing it. Still, these categories appear often enough in research that they may come up during a medication review.
| Medication category | What to review |
|---|---|
| NSAIDs such as ibuprofen, naproxen, diclofenac, and indomethacin | These pain relievers may irritate the gut lining in some people. Review how often they are used, whether symptoms worsened after starting them, and whether another pain plan is appropriate. |
| Antibiotics such as amoxicillin, ciprofloxacin, clindamycin, and azithromycin | Frequent or recent antibiotic use may shift gut bacteria in ways that can complicate UC symptoms. Timing matters, especially if diarrhea started after an infection or antibiotic course. |
| Oral contraceptives | Some studies have found a higher IBD risk with long-term use. A clinician may consider duration of use, smoking history, clot risk, and whether symptoms line up with other triggers. |
| Isotretinoin (Accutane) | This acne treatment has been discussed for possible links to bowel inflammation in some users. If symptoms began during treatment, it may be worth documenting the timeline carefully. |
| Immune-modulating therapies, including interferons, checkpoint inhibitors, and rare paradoxical reactions with TNF inhibitors | These cases are less common, but they can be more complex. The main question is whether symptoms reflect true UC, a drug-related colitis pattern, or another inflammatory reaction. |
NSAIDs
Non-steroidal anti-inflammatory drugs such as Advil, Motrin, Aleve, diclofenac, and indomethacin are often reviewed first because they are common and easy to overlook. In some patients, they may worsen gut irritation or aggravate existing UC symptoms.
Antibiotics
Antibiotics do not cause ulcerative colitis in a simple, one-step way, but repeated or recent use may affect the gut microbiome. That can matter more if symptoms began after a dental infection, sinus infection, skin infection, or another illness that required treatment.
Oral contraceptives and isotretinoin
Long-term oral contraceptive use has been studied for a possible increased risk of inflammatory bowel disease, including UC. Isotretinoin has also been debated in research, so it may deserve a careful timeline review if bowel symptoms appeared during acne treatment.
Immune therapies and paradoxical cases
Some immune-modulating medications can produce IBD-like symptoms even though other drugs in related categories are used to treat ulcerative colitis. Rare paradoxical reactions have been reported with certain TNF inhibitors, which is one reason specialist follow-up can matter when symptoms do not fit the usual pattern.
What to do if you think a medication is making symptoms worse
Do not stop a prescription on your own unless your clinician tells you to. The more useful next step is to match symptom changes to the drug name, start date, dose, and any recent infection or pain-relief use.
A medication review is usually more helpful when you bring a full list, including over-the-counter products. That list should include NSAIDs, antibiotics, acne drugs, hormonal medications, supplements, and any recent steroid tapers.
- When did the diarrhea, bleeding, cramping, or urgency begin?
- Did symptoms start after a new prescription, dose increase, or antibiotic course?
- Are you taking NSAIDs regularly for headaches, arthritis, or sports injuries?
- Have you had recent infections, travel, or food-related illness that might explain a flare?
How current ulcerative colitis treatments differ
Choosing among ulcerative colitis medications is usually less about finding one “strongest” option and more about fit. The key issues often include how active the disease is, how quickly relief is needed, whether you prefer a pill or an infusion, and what monitoring is realistic for you.
For many patients, the decision also depends on whether the goal is inducing remission, maintaining remission, or both. Prior biologic use, past steroid response, pregnancy planning, and infection history may also shape the choice.
IL-23 options and drugs often compared with Tremfya
Patients comparing newer targeted therapies may hear about Tremfya, Skyrizi, Stelara, and Omvoh. These drugs overlap in some discussion because they affect related immune pathways, but they are not interchangeable and do not all carry the same UC indication or evidence base.
If Tremfya is on your shortlist, the FDA approval information for Tremfya can help clarify its approved use and labeling. Omvoh (mirikizumab) and Stelara (ustekinumab) are also important names in this category, while Skyrizi (risankizumab) may come up because of its role in Crohn’s disease and IL-23 pathway discussions.
Velsipity and other S1P receptor modulators
Velsipity (etrasimod) and Zeposia (ozanimod) are oral S1P receptor modulators rather than injected or infused biologics. For some patients, that dosing format is a major factor when comparing options for moderate-to-severe UC.
A clinician may review heart history, liver tests, eye history, infection risk, and other baseline checks before starting this class. For a closer look at how these drugs fit into UC care, see this overview of S1P receptor modulators.
Other biologic and targeted therapies
Other commonly compared UC therapies include Humira (adalimumab), Entyvio (vedolizumab), Remicade (infliximab), Xeljanz (tofacitinib), and Rinvoq (upadacitinib). The practical differences often involve route of administration, speed of symptom control, prior exposure to TNF inhibitors, and how much lab or safety monitoring is needed.
Entyvio is often discussed for its gut-selective approach, while Remicade and Humira are TNF inhibitors with longer real-world use in UC. Xeljanz and Rinvoq are oral small-molecule treatments that may appeal to some patients, but they also bring a different risk-and-monitoring conversation.
Questions worth asking before you switch UC therapy
A short list of questions can make a treatment discussion much more useful. These tend to matter more than brand familiarity alone.
- Is this medication mainly for short-term flare control, long-term maintenance, or both?
- How is it taken: pill, injection, infusion, or a mix over time?
- How long does it typically take before response is evaluated?
- What baseline tests or ongoing labs are usually required?
- What infections, vaccines, or travel plans should be discussed first?
- If this option does not work well enough, what is the next step?
Where to verify risk and treatment information
For background on medication exposure and inflammatory bowel disease, this NIH review article is a useful starting point. For a broad patient overview of ulcerative colitis symptoms and causes, Mayo Clinic also has a clear summary at its ulcerative colitis overview page.
If you want a patient-friendly look at emerging therapies, Cleveland Clinic provides a readable overview of new treatments for ulcerative colitis. These sources can help frame the discussion, but medication decisions should still be made with your gastroenterologist or prescribing clinician.
The main takeaway
If UC symptoms changed after a medication was started, increased, or restarted, that timing may be worth reviewing rather than dismissing. Common suspects include NSAIDs, antibiotics, oral contraceptives, isotretinoin, and certain immune therapies, although the explanation is not always straightforward.
If you are already treating ulcerative colitis, the growing list of biologics and targeted drugs means there may be more than one reasonable option. The most useful comparison usually centers on fit, monitoring, route, and safety history rather than on the drug name alone.